A study in today's issue of the Journal of the American Medical Association found 67% of cardiovascular clinical trials backed by for-profit groups favored newer treatments while only 49% did so among nonprofit-backed trials. While it adds fuel to the argument that the objectivity of researchers is affected by financial ties to drug companies, the authors say there may be other explanations for the results.

Related Summaries